net_left Phương Thức Thanh Toán
Phương Thức Thanh Toán

Novartis to prioritise U.S. market, unfazed by drug pricing pushback

By Ludwig Burger and John Revill ZURICH (Reuters) - Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were...
Novartis to prioritise U.S. market, unfazed by drug pricing pushback © Reuters. FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo
let atwWrapper,atwContainerWidth,atwSliderBox,atwTotalWidth; function initATWSlider() { atwWrapper = $('.relatedInstruments'); atwSliderBox = atwWrapper.find('.slider'); atwContainerWidth = atwWrapper.width(); atwTotalWidth = atwSliderBox.width(); if(window.domainId === '2' || window.domainId === '3'){ atwWrapper.find('.sliderRight').addClass('js-slider-prev'); atwWrapper.find('.sliderLeft').addClass('js-slider-next'); } else { atwWrapper.find('.sliderRight').addClass('js-slider-next'); atwWrapper.find('.sliderLeft').addClass('js-slider-prev'); } if(atwSliderBox.find('.instrumentBox').length > 6){ atwWrapper.find('.js-slider-next').fadeIn(600); } } function atwMoveRight() { atwWrapper.find('.js-slider-prev').fadeIn(150); $(".slider > :visible:first").hide(150) $(".slider > :visible:last").next().show(150); if(!$(".slider > :visible:last").next().find('.name')()){ atwWrapper.find('.js-slider-next').fadeOut(150); return; } } function atwMoveLeft() { atwWrapper.find('.js-slider-next').fadeIn(150); $(".slider > :visible:last").hide(150); $(".slider > :visible:first").prev().show(150); if(!$(".slider > :visible:first").prev().find('.name')()){ atwWrapper.find('.js-slider-prev').fadeOut(150); return; } } initATWSlider(); //update star icon on adding/removing instrument to/from specific watchlist atwWrapper.on('click', 'label.addRow', function() { let parent = $(this).parent(); let checkedPortfolio = false; parent.find('input[type=checkbox]').each(function () { if($(this).is(':checked')){ checkedPortfolio = true; } }); let closestStar = $(this).closest('.addToPortWrapper').find('.star'); if(checkedPortfolio){ closestStar.addClass('added'); }else{ closestStar.removeClass('added'); } }); //update star icon on creating new watchlist atwWrapper.find('.js-create-watchlist-portfolio').find('a.js-create').on('click',function () { let parent = $(this).parent(); let watchlistName = parent.find('input[type=text]').val(); if(!watchlistName){ return; } let star = $(this).closest('.addToPortWrapper').find('.star'); star.addClass('added'); }); //update star icon on adding new position atwWrapper.find('.js-create-holdings-portfolio').find('.js-submit').on('click',function () { let addPositionForm = $(this).closest('.addToPortfolioPop').find('.holdingsContent'); let amount = addPositionForm.find('.js-amount').val(); if(amount < 1){ return; } let star = $(this).closest('.addToPortWrapper').find('.star'); star.addClass('added'); }); window.atwPairTypes = {"1128804":"Equities"};

By Ludwig Burger and John Revill

ZURICH (Reuters) - Swiss pharma giant Novartis said it would make growth in the United States its top geographic priority, even after laws were passed to rein in drug prices in the world's largest pharmaceutical market.

As part of an investor event, the company said on Thursday it would adopt a "U.S.-first mindset", increase the share of U.S. patients in clinical trials, build capability there and give U.S. staff and executives more say and better career opportunities within the organisation.

Novartis' aspiration is to "organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement. It ranked 10th in the U.S. market last year, the company added.

Still, Novartis said it aimed to be a top-three player in China, up from fifth place last year among multinational pharma companies, while maintaining leading positions in Germany and Japan.

U.S. President Joe Biden last month signed the Inflation Reduction Act, authorising the government to negotiate prices on some prescription drugs and cap costs for state health programme Medicare.

In 2024, the government will start negotiating what it will pay for 10 drugs that are among those accounting for the highest Medicare spending, taking effect in 2026.

Among changes coming into play sooner, price increases will have to be below the rate of inflation and out-of-pocket payments by patients on pharmacy drugs, known as Part D drugs, will be reduced .

"On the inflation caps, while challenging, we believe it's manageable and (there are) no changes for our guidance with respect to managing through the inflation caps," Novartis CEO Vas Narasimhan said at the event.

"When you look at the Part D reform and how that is capping out patient costs ... hopefully over time, you're providing some uplift in demand," he added. "If you think about certain categories, like cardiovascular disease, you could see a 3 to 10% uplift in demand."

Novartis also announced a strategy based on eight big drug brands as the company reshapes itself following the decision to spin off Sandoz, its underperforming generics business.

Its shares were down 0.9% at 0741 GMT, slightly better than the 1% decline in the STOXX Europe 600 Health Care index.

Novartis said its Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto and Scemblix therapies all held multibillion-dollar peak sales potential.

The company last month said it planned to spin off Sandoz to sharpen its focus on patented prescription medicines. The spin-off is expected to be completed in the second half of 2023, with Sandoz listed on the SIX Swiss Exchange.

Novartis has also been pruning other businesses, spinning off its Alcon (NYSE:ALC) eye care business in 2019 and last November agreeing to sell a nearly one-third voting stake in Roche.

Narasimhan also confirmed Novartis' previously stated financial targets of 4% annual sales growth through 2027 and a core operating income margin of at least 40%.

Hot Auto Trade Bot Phương Thức Thanh Toán
BROKERS ĐƯỢC CẤP PHÉP
net_home_top Ai VIF
04-10-2022 06:16:28 (UTC+7)

EUR/USD

0.9835

+0.0011 (+0.11%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

EUR/USD

0.9835

+0.0011 (+0.11%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

GBP/USD

1.1332

+0.0010 (+0.09%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (5)

Sell (3)

USD/JPY

144.46

-0.07 (-0.05%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (0)

Sell (8)

AUD/USD

0.6514

-0.0003 (-0.04%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (1)

USD/CAD

1.3627

+0.0004 (+0.03%)

Summary

↑ Sell

Moving Avg:

Buy (1)

Sell (11)

Indicators:

Buy (1)

Sell (10)

EUR/JPY

142.07

+0.09 (+0.06%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (0)

EUR/CHF

0.9756

+0.0014 (+0.14%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (1)

Gold Futures

1,709.80

+7.80 (+0.46%)

Summary

Neutral

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (2)

Sell (5)

Silver Futures

20.808

+0.219 (+1.06%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

Copper Futures

3.4232

+0.0044 (+0.13%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (10)

Sell (0)

Crude Oil WTI Futures

83.42

-0.21 (-0.25%)

Summary

Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (3)

Sell (2)

Brent Oil Futures

88.70

+3.56 (+4.18%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (7)

Natural Gas Futures

6.508

+0.006 (+0.09%)

Summary

↑ Buy

Moving Avg:

Buy (9)

Sell (3)

Indicators:

Buy (8)

Sell (0)

US Coffee C Futures

215.55

-6.00 (-2.71%)

Summary

↑ Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (0)

Sell (8)

Euro Stoxx 50

3,342.17

+23.97 (+0.72%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (0)

Sell (7)

S&P 500

3,678.43

+92.81 (+2.59%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (3)

Sell (8)

DAX

12,209.48

+95.12 (+0.79%)

Summary

Neutral

Moving Avg:

Buy (11)

Sell (1)

Indicators:

Buy (2)

Sell (4)

FTSE 100

6,908.76

+14.95 (+0.22%)

Summary

Neutral

Moving Avg:

Buy (7)

Sell (5)

Indicators:

Buy (2)

Sell (2)

Hang Seng

17,079.51

-143.32 (-0.83%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (8)

Sell (0)

US Small Cap 2000

1,709.05

+44.33 (+2.66%)

Summary

Buy

Moving Avg:

Buy (8)

Sell (4)

Indicators:

Buy (5)

Sell (2)

IBEX 35

7,462.00

+95.20 (+1.29%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (7)

Sell (1)

BASF SE NA O.N.

40.940

+1.340 (+3.38%)

Summary

↑ Sell

Moving Avg:

Buy (2)

Sell (10)

Indicators:

Buy (0)

Sell (9)

Bayer AG NA

47.95

+0.54 (+1.14%)

Summary

Sell

Moving Avg:

Buy (0)

Sell (12)

Indicators:

Buy (3)

Sell (3)

Allianz SE VNA O.N.

161.54

-0.26 (-0.16%)

Summary

Neutral

Moving Avg:

Buy (7)

Sell (5)

Indicators:

Buy (0)

Sell (10)

Adidas AG

119.00

+0.12 (+0.10%)

Summary

↑ Buy

Moving Avg:

Buy (12)

Sell (0)

Indicators:

Buy (5)

Sell (0)

Deutsche Lufthansa AG

5.716

-0.202 (-3.41%)

Summary

Sell

Moving Avg:

Buy (6)

Sell (6)

Indicators:

Buy (2)

Sell (6)

Siemens AG Class N

100.92

-0.28 (-0.28%)

Summary

↑ Sell

Moving Avg:

Buy (3)

Sell (9)

Indicators:

Buy (1)

Sell (7)

Deutsche Bank AG

7.630

-0.016 (-0.21%)

Summary

↑ Sell

Moving Avg:

Buy (4)

Sell (8)

Indicators:

Buy (0)

Sell (9)

    EUR/USD 0.9835 ↑ Buy  
    GBP/USD 1.1332 ↑ Buy  
    USD/JPY 144.46 ↑ Sell  
    AUD/USD 0.6514 ↑ Buy  
    USD/CAD 1.3627 ↑ Sell  
    EUR/JPY 142.07 ↑ Buy  
    EUR/CHF 0.9756 ↑ Buy  
    Gold 1,709.80 Neutral  
    Silver 20.808 ↑ Buy  
    Copper 3.4232 ↑ Buy  
    Crude Oil WTI 83.42 Buy  
    Brent Oil 88.70 ↑ Sell  
    Natural Gas 6.508 ↑ Buy  
    US Coffee C 215.55 ↑ Sell  
    Euro Stoxx 50 3,342.17 ↑ Sell  
    S&P 500 3,678.43 ↑ Sell  
    DAX 12,209.48 Neutral  
    FTSE 100 6,908.76 Neutral  
    Hang Seng 17,079.51 ↑ Buy  
    Small Cap 2000 1,709.05 Buy  
    IBEX 35 7,462.00 ↑ Buy  
    BASF 40.940 ↑ Sell  
    Bayer 47.95 Sell  
    Allianz 161.54 Neutral  
    Adidas 119.00 ↑ Buy  
    Lufthansa 5.716 Sell  
    Siemens AG 100.92 ↑ Sell  
    Deutsche Bank AG 7.630 ↑ Sell  
Mua/Bán 1 chỉ SJC
# So hôm qua # Chênh TG
SJC Eximbank6,540/ 6,620
(0/ 0) # 1,795
SJC HCM6,520/ 6,620
(0/ 0) # 1,798
SJC Hanoi6,520/ 6,622
(0/ 0) # 1,800
SJC Danang6,520/ 6,622
(0/ 0) # 1,800
SJC Nhatrang6,520/ 6,622
(0/ 0) # 1,800
SJC Cantho6,520/ 6,622
(0/ 0) # 1,800
Cập nhật 04-10-2022 06:16:31
Xem lịch sử giá vàng SJC: nhấn đây!
ↀ Giá vàng thế giới
$1,700.70 +36.4 2.19%
Live 24 hour Gold Chart
ʘ Giá bán lẻ xăng dầu
Sản phẩm Vùng 1 Vùng 2
RON 95-V22.12022.560
RON 95-III21.44021.860
E5 RON 92-II20.73021.140
DO 0.05S22.20022.640
DO 0,001S-V24.18024.660
Dầu hỏa 2-K21.68022.110
ↂ Giá dầu thô thế giới
WTI $82.84 -1.22 -1.49%
Brent $88.30 -0.69 -0.79%
$ Tỷ giá Vietcombank
Ngoại tệMua vàoBán ra
USD23.730,0024.040,00
EUR22.844,1424.122,55
GBP25.913,3127.017,45
JPY160,53169,94
KRW14,3417,48
Cập nhật lúc 05:22:16 04/10/2022
Xem bảng tỷ giá hối đoái
Phương Thức Thanh Toán